Biofrontera To Delist Its ADS From Nasdaq
Biofrontera AG (the “Company”) (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted
Biofrontera Announces Reduction Of Biofrontera AG Shareholding To Less Than 50% Through Warrant Exercises
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership
Biofrontera Shares Are Trading Higher After Benchmark Initiates Coverage
Benchmark initiated coverage of Biofrontera Inc (NASDAQ:BFRI) with a Buy rating and $11 price target. The Company specializes in medical dermatology, which…
Biofrontera Announces Notice Of Allowance For U.S. Method-of-Use Patent On PDT-Lamp. BZ NOTE: Benzinga Reported This Patent On Dec. 2
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has
Biofrontera AG Announced Eenrollment of First Patient in Phase I Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, is pleased to announce that it has commenced patient enrollment for its phase I safety study to evaluate the safety and tolerability of photodynamic therapy (PDT) for the treatment of mild-to-severe actinic keratosis (AK) on the face and scalp using three tubes of Ameluz® together with the new
Biofrontera Announces Notice Of Allowance For U.S. Patent Titled ‘Illumination for Photodynamic Therapy’
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has
